Filing Flows

Filing Flows › Companies › Sunshine Biopharma › Cash flow

Sunshine Biopharma cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$925K in Q2 2026 · −$5.4M over twelve months

Operating cash flow−$918K
Capital spending−$7K
Free cash flow−$925K
Cash conversion cycle142 days

Analysis

In Q2 2026, Sunshine Biopharma generated −$918K of operating cash flow and spent $7K on capital projects, leaving free cash flow of −$925K. That is $508K more than in Q2 2025 (−$1.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$5.4M; the largest uses were operating cash flow ($5.4M), other investing ($165K), capital spending ($19K); besides operations, cash came from shares issued ($5.1M), other financing ($3.4M); the cash balance rose by $3.4M.

Operating cash flow was −$918K against net income of −$1.6M. The largest differences: inventory +$794K, payables −$157K, prepaid and other assets +$134K.

Its cash conversion cycle was 142 days (receivables 40 + inventory 168 − payables 66).

Free cash flow

Sunshine Biopharma: free cash flow by quarterSunshine Biopharma: free cash flow by quarter−$1.9MQ3 2024−$3.5MQ4 2024−$1.7MQ1 2025−$1.4MQ2 2025−$755KQ3 2025−$1.6MQ4 2025−$2.1MQ1 2026−$925KQ2 2026
Operating cash flow less capital spending.
Sunshine Biopharma: operating cash flow against capital spendingSunshine Biopharma: operating cash flow against capital spendingOperating cash flowCapital spending−$1.4M$517KQ3 2024−$3.4M$103KQ4 2024−$1.7M$7KQ1 2025−$1.3M$160KQ2 2025−$747K$8KQ3 2025−$1.6M−$1KQ4 2025−$2.1M$5KQ1 2026−$918K$7KQ2 2026
Latest (Q2 2026): Operating cash flow −$918K, Capital spending $7K.

Capital allocation, year by year

Sunshine Biopharma: where the cash came from (up) and went (down), by fiscal yearSunshine Biopharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow −$1.8MFY2021: Net borrowing $2.9M$2.9MFY2021FY2022: Operating cash flow −$5.2MFY2022: Net borrowing −$1.9MFY2022: Shares issued $30.4MFY2022: Capital spending −$194KFY2022: Acquisitions −$14.3M$30.4MFY2022FY2023: Operating cash flow −$8.8MFY2023: Shares issued $4.1MFY2023: Capital spending −$82KFY2023: Buybacks −$541K$4.1MFY2023FY2024: Operating cash flow −$12.5MFY2024: Shares issued $8.5MFY2024: Capital spending −$1.7MFY2024: Buybacks −$3.1M$8.5MFY2024FY2025: Operating cash flow −$5.3MFY2025: Shares issued $1.8MFY2025: Capital spending −$174K$1.8MFY2025
Over these 5 years operating cash flow totalled −$33.7M; the largest uses were operating cash flow ($33.7M) and acquisitions ($14.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$13.7M
Debtnone
Net cash$13.7M
Cash runway2.6 years

Sunshine Biopharma is burning cash: its operations consume cash, a free cash flow of −$5.4M a year at the current rate against $13.7M of cash and investments: a runway of about 2.6 years before any new financing.

Where the cash came from and went

Sunshine Biopharma: sources (+) and uses (−) of cash, Q2 2026Sunshine Biopharma: sources (+) and uses (−) of cash, Q2 2026Other financing$7.8MCash drawn (+) / kept (−)−$6.9MOperating cash flow−$918KCapital spending−$7KOther investing$2K
Sunshine Biopharma: sources (+) and uses (−) of cash, TTM to Q2 2026Sunshine Biopharma: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$5.4MShares issued$5.1MOther financing$3.4MCash drawn (+) / kept (−)−$3.4MExchange rates$451KOther investing−$165KCapital spending−$19K

From profit to cash

Sunshine Biopharma: net income to operating cash flow, Q2 2026Sunshine Biopharma: net income to operating cash flow, Q2 2026Net income−$1.6MDepreciation & amortization$78KReceivables−$89KInventory$794KPayables−$157KPrepaid and other assets$134KIncome taxes payable−$175Operating cash flow−$918K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20264016866142
Q1 20264220382162
Q4 20254122898171
Q3 20253819679155
Q2 20253418975148
Q1 20253716977129
Q4 20243414969115
Q3 20243915175115

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$918K−$7K—−$6.9M−$925K
Q1 2026−$2.1M−$5K—$2.2M−$2.1M
Q4 2025−$1.6M$1K—$183K−$1.6M
Q3 2025−$747K−$8K—$999K−$755K
Q2 2025−$1.3M−$160K$1.8M−$2.2M−$1.4M
Q1 2025−$1.7M−$7K—$1.6M−$1.7M
Q4 2024−$3.4M−$103K—$2.5M−$3.5M
Q3 2024−$1.4M−$517K—−$699K−$1.9M

Sunshine Biopharma: income statement and cash flow

Sunshine Biopharma, Q2 2026: revenue $9.3M (-2% year over year), operating margin -17.4%. The chart follows the revenue to costs, profit and cash.

Sunshine Biopharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.